arrow
S

Sydney Tang

The University of Hong Kong
H指数:67
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: insights from the CREDENCE trial

卡格列净在CKD患者中不同联合用药负担下的疗效和安全性具有一致性:来自CREDENCE试验的见解

2026-09-040
OAAI
The path to safe, equitable and sustainable dialysis provision for people with chronic kidney disease

为慢性肾脏病患者提供安全,公平和可持续的透析服务

2026-01-210
PRE
Nature Medicine Commission on dialysis policy in low- and middle-income countries

自然医学委员会在低收入和中等收入国家的透析政策

2026-01-210
PRE
Retrospective Analysis of Graft Loss Risk in Patients with BK Polyomavirus Associated Nephropathy in Relation to Rejection Status in a Multicentre Cohort with Regular Surveillance of BK Polyomavirus and Donor-Specific Antibody

BK多瘤病毒相关性肾病患者移植肾丢失风险的回顾性分析:多中心队列中与排斥状态相关的BK多瘤病毒及供者特异性抗体常规监测研究

2025-11-010
OA
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

KDIGO 2025年免疫球蛋白A肾病(IgAN)和免疫球蛋白A血管炎(IgAV)管理临床实践指南的执行摘要

2025-09-180
OAAI
Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia

亚洲2型糖尿病患者的CKD管理中已建立全球指南的实施

2025-09-011
PRE